SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-032169
Filing Date
2020-03-12
Accepted
2020-03-12 08:04:23
Documents
6
Period of Report
2020-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2012488-1_8k.htm 8-K 24796
2 EXHIBIT 4.1 tm2012488d1_ex4-1.htm EX-4.1 83646
3 EXHIBIT 10.1 tm2012488d1_ex10-1.htm EX-10.1 217859
4 EXHIBIT 99.1 tm2012488d1_ex99-1.htm EX-99.1 15964
5 GRAPHIC image_001.jpg GRAPHIC 3481
6 GRAPHIC tm2012488d1_ex4-1img001.jpg GRAPHIC 3537
  Complete submission text file 0001104659-20-032169.txt   353683
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 20707208
SIC: 2836 Biological Products, (No Diagnostic Substances)